Click here to view the report.

October 14, 2013, ROCKVILLE, MD – Aeras has been awarded Best Cause-Related Video for its film series, EXPOSED: The Race Against Tuberculosis by PR Daily. The PR Daily Digital PR award winners include some of the most recognized names in public relations and communications from around the world. The EXPOSED series also won an honorable mention under “Best Digital PR Campaign – Nonprofit Sector.”

Watch the four-part series of short films on the deadly global TB epidemic and the race to develop new tools to prevent it, now with subtitles in seven languages: http://www.aeras.org/exposed

ROCKVILLE, Md. (August 19, 2013)— The government of Australia has expanded its role in the global battle against tuberculosis, providing a grant of AUS$2.5 million to fund the quest for an effective vaccine against a silent killer that infects one out of three people worldwide.

Beijing, China/Rockville, MD, USA–August 2, 2013 – With the global tuberculosis epidemic becoming more deadly, costly, and difficult to treat, Chinese Center for Disease Control and Prevention (China CDC) and Aeras today signed a memorandum of understanding to advance research and development of new tuberculosis vaccines. An improved TB vaccine offers the best hope for eliminating this airborne infectious disease that kills 1.4 million people worldwide each year.

Making new TB vaccines available to the world over the next 10-15 years is estimated to cost approximately €600 million, utilizing a highly efficient portfolio approach and adequate funding.

Watch the four-part series of short films on the deadly global TB epidemic and the race to develop new tools to prevent it:

Rockville, MD, US, Oxford, UK and Basel, Switzerland - May 7, 2013 - Aeras, a nonprofit biotech advancing TB vaccines for the world, the University of Oxford and Okairos, a biopharmaceutical company specializing in T-cell vaccines, today announced a $2.9 million grant to Aeras in support of a collaboration among the three parties to support the development of vaccines against tuberculosis, HIV and malaria.

CAPE TOWN – 25 March 2013 – At a time of growing global concern about the rising level of drug-resistant strains of tuberculosis in South Africa and worldwide, the world’s top TB vaccine experts are meeting this week, the first time this scientific forum has been held in Africa, where they will present new research aimed at advancing development of vaccines against the deadly airborne disease.

Vaccine candidate was generally well tolerated, meeting the study’s primary objective of safety; Vaccine candidate did not provide statistically-significant protection in preventing TB disease in infants previously vaccinated with BCG.